<DOC>
	<DOCNO>NCT01841164</DOCNO>
	<brief_summary>The trial investigator-driven research study subject intermittent asthma , aim explore likelihood functionally important separate leukotriene E4 ( LTE4 ) receptor airways and/or inflammatory cell human subject asthma . Mostly basis experiment mice model , prevail view suggest present class anti-leukotriene drug insufficient block pro-inflammatory bronchoconstrictive effect LTE4 . It establish u group LTE4 stable long-lived leukotriene . The study establish effect oral treatment highly selective CysLT1-receptor antagonist , montelukast , bronchial responsiveness inhale LTE4 subject intermittent asthma</brief_summary>
	<brief_title>A Mechanistic Study Evaluate Efficacy Montelukast Airway Function Asthma</brief_title>
	<detailed_description>Rationale : It propose specific LTE4-receptor cause infiltration inflammatory cell bronchoconstriction . This receptor block current class clinically use antileukotriene drug . The proposal receive circumstantial support animal model , test control study subject asthma . Study design : The study placebo-controlled , double-blind , randomised , cross-over design . A screening period precede randomize phase . This include routine haematology , blood chemistry urinalysis , baseline measurement exhale nitric oxide , airway responsiveness inhaled methacholine , separate day , airway responsiveness inhale LTE4 . Provided subject fulfill inclusion exclusion criterion , subject randomize receive medication montelukast match placebo 5 7 day . The intervention evaluate inhalation challenge set use rise dose cumulative protocol inhale LTE4 induce standardise bronchoconstriction ( 25 % drop lung function ) . The LTE4 challenge test perform last treatment day , last dose study medication take research laboratory . Sampling urine , blood induce sputum do measurement lipid mediator cellular response .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>1 . Be age 1855 year inclusive 2 . Have diagnose history asthma define least one following : 1. response standard asthma treatment 2. episodic wheeze 3. change lung function short period time 3 . Be nonsmoker last two year total smoking le 5 packyears 4 . Display positive methacholine challenge test evidence PD20 ( provocative dose cause 20 % fall force expiratory volume one second ) ≤ 3621 µg cumulate dose within 8 week prior screen screen visit . 5 . Have stable intermittent asthma , use bronchodilator therapy need last 4 week . 6 . Produce FEV1 ( forced expiratory volume one second ) ≥ 70 % predict 1 . Any significant respiratory disease , asthma . 2 . Subjects seasonal asthma may include season . 3 . Use : oral inhaled glucocorticosteroid treatment last 4 week prior inclusion study inhale longacting oral beta2agonists , anticholinergic bronchodilator , antihistamine , theophylline , chromones antileukotrienes within 2 week screen regular NSAIDs drug inhibit enzyme CYP3A ( e.g . ritonavir , azol , antifungal , macrolides ) betablocking agent 4 . Upper low respiratory tract infection within 4 week inclusion 5 . Evidence ( medical history physical examination ) disease investigator mind would affect result study , particular liver disease and/or sign liver function impairment 6 . Participating another study four week prior screen 7 . Females pregnant , intend lactate 8 . Subjects history aspirinsensitive respiratory disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Leukotriene responsiveness</keyword>
	<keyword>LTE4</keyword>
	<keyword>asthma</keyword>
	<keyword>airway hyperresponsiveness</keyword>
	<keyword>bronchoprovocation</keyword>
	<keyword>anti-asthmatic agent</keyword>
	<keyword>human</keyword>
</DOC>